Neurodegeneration in multiple sclerosis
WIREs Mechanisms of Disease · 2023-01 · 15 (1)
DOI: 10.1002/wsbm.1583 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, online erschienen am 10.08.2022. Verfasst von Gabrielle M Mey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, and Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Neurodegenerative Diseases. Die Arbeit wurde bisher 140-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NINDS NIH HHS, National Eye Institute.
Abstract (Originalsprache)
Axonal loss in multiple sclerosis (MS) is a key component of disease progression and permanent neurologic disability. MS is a heterogeneous demyelinating and neurodegenerative disease of the central nervous system (CNS) with varying presentation, disease courses, and prognosis. Immunomodulatory therapies reduce the frequency and severity of inflammatory demyelinating events that are a hallmark of MS, but there is minimal therapy to treat progressive disease and there is no cure. Data from patients with MS, post‐mortem histological analysis, and animal models of demyelinating disease have elucidated patterns of MS pathogenesis and underlying mechanisms of neurodegeneration. MRI and molecular biomarkers have been proposed to identify predictors of neurodegeneration and risk factors for disease progression. Early signs of axonal dysfunction have come to light including impaired mitochondrial trafficking, structural axonal changes, and synaptic alterations. With sustained inflammation as well as impaired remyelination, axons succumb to degeneration contributing to CNS atrophy and worsening of disease. These studies highlight the role of chronic demyelination in the CNS in perpetuating axonal loss, and the difficulty in promoting remyelination and repair amidst persistent inflammatory insult. Regenerative and neuroprotective strategies are essential to overcome this barrier, with early intervention being critical to rescue axonal integrity and function. The clinical and basic research studies discussed in this review have set the stage for identifying key propagators of neurodegeneration in MS, leading the way for neuroprotective therapeutic development. This article is categorized under: Immune System Diseases > Molecular and Cellular Physiology Neurological Diseases > Molecular and Cellular Physiology
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, and Case Western Reserve University, Cleveland, Ohio, USA.
- Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
ORCID-Profile: Gabrielle M Mey, Kedar R Mahajan, Tara M DeSilva
Förderung
- NEI NIH HHS
- NINDS NIH HHS
- National Eye Institute
- National Multiple Sclerosis Society
- National Science Foundation of Sri Lanka
- Research to Prevent Blindness
Zitieren
APA
Mey, G. M., Mahajan, K. R., & DeSilva, T. M. (2023). Neurodegeneration in multiple sclerosis. WIREs Mechanisms of Disease, 15(1). https://doi.org/10.1002/wsbm.1583
Vancouver
Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. WIREs Mechanisms of Disease. 2023;15(1). doi:10.1002/wsbm.1583
BibTeX
@article{Mey2023,
author = {Mey, Gabrielle M and Mahajan, Kedar R and DeSilva, Tara M},
title = {Neurodegeneration in multiple sclerosis},
journal = {WIREs Mechanisms of Disease},
year = {2023},
volume = {15},
number = {1},
doi = {10.1002/wsbm.1583}
}
EUVIMED